Octreotide Injection

342 interactions 555 cited references

Also sold as: Bynfezia Bynfezia® Mycapssa Sandostatin Sandostatin® Sandostatin® LAR Depot

About Octreotide Injection

Octreotide immediate-release injection is used to decrease the amount of growth hormone (a natural substance) produced by people with acromegaly (condition in which the body produces too much growth hormone, causing enlargement of the hands, feet, and facial features; joint pain; and other symptoms) who cannot be treat… Read the full Octreotide Injection drug information page →

Medically reviewed by Dr. Brian Staiger, PharmD, BCPS · Updated Aug 10, 2026 · Editorial policy · Data sources

Sources: FDA prescribing information (Structured Product Labeling), the published literature cited in each entry, DDInter 2.0 (a major open-access drug-interaction database), and legacy DrugBank interaction data distributed by the NIH's RxNav service (decommissioned in 2024) — analyzed and reviewed by our pharmacist team. How we build this library →

Most serious with: Dronedarone Levoketoconazole Levomethadyl Mesoridazine Pimozide Ziprasidone

13 Contraindicated 325 Major 4 Moderate

All (342) Contraindicated (13) Major (325) Moderate (4)

Major

Octreotide Injection Fexinidazole An increased risk of QT interval prolongation Details Octreotide Injection Fingolimod Gilenya Increased risk of QT interval prolongation Details Octreotide Injection Flecainide Tambocor® An increased risk of cardiotoxicity (QT prolongation, torsades de pointes, cardiac arrest) Details Octreotide Injection Flibanserin Addyi Increased exposure of CYP3A4 substrates with narrow therapeutic index Details Octreotide Injection Fluconazole Diflucan An increased risk of QT interval prolongation Details Octreotide Injection Fluoxetine RECONCILE An increased risk of cardiotoxicity (QT interval prolongation, torsades de pointes, cardiac arrest) Details Octreotide Injection Fluphenazine An increased risk of cardiotoxicity (QT prolongation, torsades de pointes, cardiac arrest) Details Octreotide Injection Formoterol Perforomist Increased risk of QT interval prolongation and an increased risk of cardiovascular adverse effects Details Octreotide Injection Foscarnet Foscavir An increased risk of cardiotoxicity (QT prolongation, torsades de pointes, cardiac arrest) Details Octreotide Injection Fosfomycin Contepo An increased risk of QT interval prolongation Details Octreotide Injection Fosphenytoin Cerebyx An increased risk of QT interval prolongation Details Octreotide Injection Fostemsavir Rukobia Increased risk of torsade de pointes Details Octreotide Injection Gallium Ga 68 Dotatate Reduced efficacy of gallium Ga 68 dotatate Details Octreotide Injection Gallium Ga 68 Dotatoc Decreased gallium Ga 68 dotatoc efficacy Details Octreotide Injection Gatifloxacin Zymaxid An increased risk of QT interval prolongation Details Octreotide Injection Gemifloxacin Factive An increased risk of cardiotoxicity (QT prolongation, torsades de pointes, cardiac arrest) Details Octreotide Injection Gepirone Exxua An increased risk of QT interval prolongation and cardiac arrhythmias Details Octreotide Injection Gepotidacin Blujepa An increased risk of QT interval prolongation Details Octreotide Injection Gestodene Decreased bioavailability and decreased efficacy of combined oral contraceptives or increased breakthrough bleeding Details Octreotide Injection Givinostat Duvyzat Increased risk of QT interval prolongation and torsade de pointes Details Octreotide Injection Glasdegib Daurismo Increased risk of QT interval prolongation Details Octreotide Injection Glimepiride Amaryl An increased risk of hypoglycemia and impaired glucose regulation Details Octreotide Injection Glipizide Glucotrol An increased risk of hypoglycemia and impaired glucose regulation Details Octreotide Injection Glyburide DiaBeta® An increased risk of hypoglycemia and impaired glucose regulation Details Octreotide Injection Goserelin Increased risk of QT interval prolongation Details Octreotide Injection Granisetron An increased risk of QT interval prolongation Details Octreotide Injection Halofantrine An increased risk of cardiotoxicity (QT prolongation, torsades de pointes, cardiac arrest) Details Octreotide Injection Haloperidol An increased risk of cardiotoxicity (QT prolongation, torsade de pointes, cardiac arrest) Details Octreotide Injection Halothane An increased risk of cardiotoxicity (QT prolongation, torsades de pointes, cardiac arrest) Details Octreotide Injection Histrelin Supprelin Increased risk of QT interval prolongation Details Octreotide Injection Hydroquinidine An increased risk of cardiotoxicity (QT prolongation, torsades de pointes, cardiac arrest) Details Octreotide Injection Hydroxychloroquine Plaquenil Increased risk of QT interval prolongation Details Octreotide Injection Hydroxyzine An increased risk of QT interval prolongation Details Octreotide Injection Ibutilide Corvert An increased risk of cardiotoxicity (QT prolongation, torsades de pointes, cardiac arrest) Details Octreotide Injection Iloperidone Fanapt An increased risk of QT interval prolongation and an increased risk of cardiac arrhythmia Details Octreotide Injection Imipramine An increased risk of cardiotoxicity (QT prolongation, torsades de pointes, cardiac arrest) Details Octreotide Injection Inotuzumab Ozogamicin Besponsa Increased risk of QT interval prolongation Details Octreotide Injection Insulin Afrezza An increased risk of hypoglycemia and impaired glucose regulation Details Octreotide Injection Insulin Aspart, Recombinant Fiasp An increased risk of hypoglycemia and impaired glucose regulation Details Octreotide Injection Insulin Bovine An increased risk of hypoglycemia and impaired glucose regulation Details

Check another drug

Still have questions about this combination?

Every question gets a real answer from a licensed pharmacist — free, and usually within a day.

Ask the pharmacist

Educational information only, not medical advice. Always confirm interactions with your pharmacist or prescriber before making any change to your medications.